The Adenosine pathway
Adenosine (ADO) has been known to modulate immune function for nearly half a century. Levels of extracellular ADO are controlled by the hydrolysis of extracellular adenosine triphosphate by ecto-nucleotidases such as CD39 and CD73. Adenosine signaling impairs the function of a variety of immune cells, including T cells, NK cells and myeloid cells. Activation of cAMP-dependent PKA and blockade of NF-KB and JAK-STAT pathways are generalized mechanisms by which A2A and A2B adenosine receptors suppress immune cells.
The Adenosine pathway
Big Data &
new targets
Leveraging Big Data of Immune Checkpoint Blockade Response Identifies Novel Potential Targets
In our recent study in Annals of Oncology, Dr Yacine Bareche et al. identified a gene expression signature, called PredictIO, that demonstrates superior ability to predict clinical response to immunotherapy.
​​
​
With our colleagues from the Haibe-Kains lab we developed an open-source web-application (PredictIO.ca) that allows researchers to explore their biomarker of interest.